Abstract
Thymic carcinoma is a rare cancer with a poor prognosis in unresectable cases. There is no established standard chemotherapy for the treatment of thymic carcinoma because evidence has been obtained in single-arm trials with a small number of patients. In clinical practice, carboplatin +paclitaxel (CP), S-1 (oral fluorouracil), sunitinib, and lenvatinib have been used in Japan. However, the clinical impact of these chemotherapy regimens remains unclear. In addition, some patients receiving these treatments experience only increased liver metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
